Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Completed · Phase 1

Conditions studied: Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue

In brief

Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.

Key facts

Study ID

NCT00187174

Run by

St. Jude Children's Research Hospital

People needed

41

Starts

2004-10-01

Expected to finish

2008-10-01

Last updated by the study team

2015-03-04

Who can join

Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adequate performance status
• Adequate bone marrow, kidney, heart, and liver function

You may not qualify if…

• Must not be receiving concomitant anti-cancer treatment
• Must not be pregnant

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.